A phase II study (AK112‐201) on ivonescimab combined with chemotherapy for advanced NSCLC, a phase Ib/II study (AK112‐202) on ivonescimab as first‐ or second‐line therapy for advanced NSCLC, and a phase III study (AK112‐301) of ivonescimab plus chemotherapy for advanced NSCLC with epidermal growth factor receptor variant were also conducted in China and have been published [17, 18, 19]. Here, EGFR is linked to non-small cell lung carcinoma.